Market Overview

UPDATE: J.P. Morgan Downgrades Avid Technology to Neutral Following Trimmed Estimates


In a report published Monday, J.P. Morgan analyst Paul Coster downgraded the rating on Avid Technology (NASDAQ: AVID) from Overweight to Neutral, and lowered the price target from $8.50 to $6.50.

In the report, J.P. Morgan noted, “AVID's path back to growth, profitability and timely filing of quarterly financials remains uncertain. The firm continues to play a key role in professional media creation, but much of the market (ingest, editing and storage) has matured weighing on growth prospects in the near-term. We expect the new leadership team to focus on post-production, and distribution moving forward but the reconfiguration of the firm's product strategy to address that opportunity could last six months or more. We are cutting estimates to reflect this transition, and lowering our Price Target to $6.50. We are also downgrading the stock to Neutral.”

Avid Technology closed on Friday at $5.88.

Latest Ratings for AVID

May 2019Initiates Coverage OnBuy
Jan 2019UpgradesSellNeutral
Nov 2018DowngradesHoldSell

View More Analyst Ratings for AVID
View the Latest Analyst Ratings

Posted-In: J.P. Morgan Paul CosterAnalyst Color Downgrades Analyst Ratings


Related Articles (AVID)

View Comments and Join the Discussion!

Latest Ratings

WEEDCantor FitzgeraldMaintains18.9
TGTXCantor FitzgeraldMaintains19.0
SPLKCleveland ResearchDowngrades
IQVWolfe ResearchUpgrades
PRAHWolfe ResearchUpgrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Insight Announces Its Involvement in the Microsoft Devices Program

UPDATE: Piper Jaffray Upgrades Regeneron Pharmaceuticals to Overweight Following EYLEA Launch